<p>Pyxis Oncology, Inc.（纳斯达克代码：PYXS - 获取免费报告）获得了七家覆盖该公司的券商一致推荐的 “适度买入” 评级，Marketbeat.com 报道。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，五位给予了买入评级。在过去一年中，对该股票发布评级的券商的平均 12 个月目标价格为 7.20 美元。</p>
<p>获取 <strong>Pyxis Oncology</strong> 的提醒：</p>
<p>多家研究机构已对 PYXS 发布了报告。华尔街禅在 12 月 20 日的研究报告中将 Pyxis Oncology 的股票评级从 “持有” 下调至 “卖出”。古根海姆在 11 月 4 日的研究报告中将 Pyxis Oncology 的目标价格从 5.00 美元上调至 7.00 美元，并给予该公司 “买入” 评级。韦斯评级在 10 月 8 日的研究报告中重申了对 Pyxis Oncology 的 “卖出（d-）” 评级。扎克斯研究在 11 月 4 日的研究报告中将 Pyxis Oncology 的评级从 “强力买入” 下调至 “持有”。最后，斯蒂芬斯在 11 月 24 日的研究报告中将 Pyxis Oncology 的目标价格从 5.00 美元上调至 8.00 美元，并给予该股票 “超配” 评级。</p>
<p><strong>查看我们最新的 Pyxis Oncology 股票分析</strong></p>
<h2>Pyxis Oncology 股票表现</h2>
<p>PYXS 的股票在周五开盘价为 1.15 美元。该公司的 50 日移动平均价格为 3.59 美元，200 日移动平均价格为 2.37 美元。该公司的市值为 7160 万美元，市盈率为-0.72，贝塔值为 1.45。Pyxis Oncology 的 52 周低点为 0.83 美元，52 周高点为 5.55 美元。</p>
<p>Pyxis Oncology（纳斯达克代码：PYXS - 获取免费报告）最近在 11 月 3 日发布了季度财报。该公司报告每股收益（EPS）为-0.35 美元，超出市场共识预期的-0.36 美元，超出幅度为 0.01 美元。整体来看，研究分析师预测 Pyxis Oncology 在当前年度将发布-1.04 美元的每股收益。</p>
<h2>对 Pyxis Oncology 的对冲基金看法</h2>
<p>机构投资者最近调整了对该股票的持有情况。Catalyst Funds Management Pty Ltd 在第二季度购买了 Pyxis Oncology 的新头寸，价值约为 26,000 美元。Kingstone Capital Partners Texas LLC 在第二季度获得了 Pyxis Oncology 的新股份，价值 37,000 美元。XTX Topco Ltd 在第二季度购买了 Pyxis Oncology 的新头寸，价值 40,000 美元。Velan Capital Investment Management LP 在第二季度获得了 Pyxis Oncology 的新头寸，价值 44,000 美元。最后，Persistent Asset Partners Ltd 在第三季度购买了 Pyxis Oncology 的新股份，价值 77,000 美元。目前，39.09% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Pyxis Oncology</h2>
<p>（获取免费报告）</p>
<p>Pyxis Oncology（纳斯达克代码：PYXS）是一家临床阶段的生物技术公司，专注于靶向肿瘤治疗的发现和开发。该公司的平台以抗体药物偶联物（ADCs）为中心，直接将强效的有丝分裂抑制剂输送到癌细胞，利用新型载荷设计来干扰细胞分裂。通过将高度特异性的抗体与创新的细胞毒性药物结合，Pyxis Oncology 旨在改善治疗窗口并减少传统化疗常见的非靶向毒性。</p>
<p>自成立以来，Pyxis Oncology 已建立了一条针对多种实体肿瘤抗原的早期 ADC 候选药物管线。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Pyxis Oncology</li>
<li>黄金警报</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>关于中国的震撼揭露</li>
<li>请勿删除，立即阅读</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFlYUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFlYUw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Pyxis Oncology 吗？</h2>
<p>在你考虑 Pyxis Oncology 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Pyxis Oncology 并不在名单上。</p>
<p>虽然 Pyxis Oncology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PYXS

<p>Pyxis Oncology, Inc.（纳斯达克代码：PYXS）获得了七家券商的共识推荐为 “适度买入”。一位分析师将其评级为卖出，一位为持有，五位为买入。12 个月的平均目标价为 7.20 美元。最近的报告显示评级不一，一些公司下调了评级，而另一些则提高了目标价。该股票开盘价为 1.15 美元，市值为 7160 万美元。机构投资者持有该股票的 39.09%。Pyxis 专注于开发使用抗体药物偶联物的靶向肿瘤治疗</p>

<p>Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the seven brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.20.</p>
<div class="lb-trans"><p>Pyxis Oncology, Inc.（纳斯达克代码：PYXS - 获取免费报告）获得了七家覆盖该公司的券商一致推荐的 “适度买入” 评级，Marketbeat.com 报道。一位研究分析师对该股票给予了卖出评级，一位给予了持有评级，五位给予了买入评级。在过去一年中，对该股票发布评级的券商的平均 12 个月目标价格为 7.20 美元。</p>
</div><p>Get <strong>Pyxis Oncology</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Pyxis Oncology</strong> 的提醒：</p>
</div><p>A number of research firms have issued reports on PYXS. Wall Street Zen downgraded shares of Pyxis Oncology from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, December 20th. Guggenheim raised their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Zacks Research lowered Pyxis Oncology from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 4th. Finally, Stephens lifted their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an &#34;overweight&#34; rating in a research note on Monday, November 24th.</p>
<div class="lb-trans"><p>多家研究机构已对 PYXS 发布了报告。华尔街禅在 12 月 20 日的研究报告中将 Pyxis Oncology 的股票评级从 “持有” 下调至 “卖出”。古根海姆在 11 月 4 日的研究报告中将 Pyxis Oncology 的目标价格从 5.00 美元上调至 7.00 美元，并给予该公司 “买入” 评级。韦斯评级在 10 月 8 日的研究报告中重申了对 Pyxis Oncology 的 “卖出（d-）” 评级。扎克斯研究在 11 月 4 日的研究报告中将 Pyxis Oncology 的评级从 “强力买入” 下调至 “持有”。最后，斯蒂芬斯在 11 月 24 日的研究报告中将 Pyxis Oncology 的目标价格从 5.00 美元上调至 8.00 美元，并给予该股票 “超配” 评级。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Pyxis Oncology</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Pyxis Oncology 股票分析</strong></p>
</div><h2>Pyxis Oncology Stock Performance</h2>
<div class="lb-trans"><h2>Pyxis Oncology 股票表现</h2>
</div><p>Shares of PYXS opened at $1.15 on Friday. The business's fifty day moving average price is $3.59 and its two-hundred day moving average price is $2.37. The firm has a market capitalization of $71.60 million, a price-to-earnings ratio of -0.72 and a beta of 1.45. Pyxis Oncology has a 52 week low of $0.83 and a 52 week high of $5.55.</p>
<div class="lb-trans"><p>PYXS 的股票在周五开盘价为 1.15 美元。该公司的 50 日移动平均价格为 3.59 美元，200 日移动平均价格为 2.37 美元。该公司的市值为 7160 万美元，市盈率为-0.72，贝塔值为 1.45。Pyxis Oncology 的 52 周低点为 0.83 美元，52 周高点为 5.55 美元。</p>
</div><p>Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01. As a group, research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.</p>
<div class="lb-trans"><p>Pyxis Oncology（纳斯达克代码：PYXS - 获取免费报告）最近在 11 月 3 日发布了季度财报。该公司报告每股收益（EPS）为-0.35 美元，超出市场共识预期的-0.36 美元，超出幅度为 0.01 美元。整体来看，研究分析师预测 Pyxis Oncology 在当前年度将发布-1.04 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Pyxis Oncology</h2>
<div class="lb-trans"><h2>对 Pyxis Oncology 的对冲基金看法</h2>
</div><p>Institutional investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd bought a new position in Pyxis Oncology during the 2nd quarter worth approximately $26,000. Kingstone Capital Partners Texas LLC acquired a new stake in Pyxis Oncology in the second quarter worth $37,000. XTX Topco Ltd bought a new position in shares of Pyxis Oncology during the second quarter worth $40,000. Velan Capital Investment Management LP acquired a new position in shares of Pyxis Oncology in the 2nd quarter valued at $44,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of Pyxis Oncology in the 3rd quarter valued at $77,000. 39.09% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近调整了对该股票的持有情况。Catalyst Funds Management Pty Ltd 在第二季度购买了 Pyxis Oncology 的新头寸，价值约为 26,000 美元。Kingstone Capital Partners Texas LLC 在第二季度获得了 Pyxis Oncology 的新股份，价值 37,000 美元。XTX Topco Ltd 在第二季度购买了 Pyxis Oncology 的新头寸，价值 40,000 美元。Velan Capital Investment Management LP 在第二季度获得了 Pyxis Oncology 的新头寸，价值 44,000 美元。最后，Persistent Asset Partners Ltd 在第三季度购买了 Pyxis Oncology 的新股份，价值 77,000 美元。目前，39.09% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Pyxis Oncology</h2>
<div class="lb-trans"><h2>关于 Pyxis Oncology</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.</p>
<div class="lb-trans"><p>Pyxis Oncology（纳斯达克代码：PYXS）是一家临床阶段的生物技术公司，专注于靶向肿瘤治疗的发现和开发。该公司的平台以抗体药物偶联物（ADCs）为中心，直接将强效的有丝分裂抑制剂输送到癌细胞，利用新型载荷设计来干扰细胞分裂。通过将高度特异性的抗体与创新的细胞毒性药物结合，Pyxis Oncology 旨在改善治疗窗口并减少传统化疗常见的非靶向毒性。</p>
</div><p>Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.</p>
<div class="lb-trans"><p>自成立以来，Pyxis Oncology 已建立了一条针对多种实体肿瘤抗原的早期 ADC 候选药物管线。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Pyxis Oncology</li>
<li>GOLD ALERT</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>Bombshell Exposé on China Strikes</li>
<li>Do not delete, read immediately</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Pyxis Oncology</li>
<li>黄金警报</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>关于中国的震撼揭露</li>
<li>请勿删除，立即阅读</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFlYUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PYXS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pyxis Oncology Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Pyxis Oncology 吗？</h2>
</div><p>Before you consider Pyxis Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Pyxis Oncology 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pyxis Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Pyxis Oncology 并不在名单上。</p>
</div><p>While Pyxis Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Pyxis Oncology 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Pyxis Oncology, Inc.（纳斯达克股票代码：PYXS）被券商一致推荐为 “适度买入”